Circulating, Imaging, and Genetic Biomarkers in Cardiovascular Risk Prediction

Trends in Cardiovascular Medicine

Volumn 21, Issue 4, 2011, Pages 105-112

  Ge, Yin ^a   Wang, Thomas J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; HIGH DENSITY LIPOPROTEIN;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; DISEASE ACTIVITY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HIGH THROUGHPUT SCREENING; HUMAN; IMAGING SYSTEM; MEDICAL TECHNOLOGY; METABOLOMICS; MOLECULAR BIOLOGY; MOLECULAR RECOGNITION; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

BIOLOGICAL MARKERS; CARDIAC IMAGING TECHNIQUES; CARDIOVASCULAR DISEASES; GENETIC MARKERS; HUMANS; RISK ASSESSMENT;

EID: 84861905041     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2012.03.007     Document Type: Review

References (79)

1. Achenbach S., Ropers D., Pohle K., et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: A prospective evaluation. Circulation 2002, 106:1077-1082.
2. Agatston A.S., Janowitz W.R., Hildner F.J., et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990, 15:827-832.
3. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95. Biomarkers Definitions Working Group.
4. 1H-NMR-based metabonomics. Nat Med 2002, 8:1439-1444.
5. Buckley D.I., Fu R., Freeman M., et al. C-reactive protein as a risk factor for coronary heart disease: A systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med 2009, 151:483-495.
6. Cao J.J., Arnold A.M., Manolio T.A., et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: The Cardiovascular Health Study. Circulation 2007, 116:32-38.
7. Cook N.R., Buring J.E., Ridker P.M. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006, 145:21-29.
8. Daniels L.B., Clopton P., Laughlin G.A., et al. Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: The Rancho Bernardo study. Circulation 2011, 123:2101-2110.
9. de Lemos J.A., Drazner M.H., Omland T., et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010, 304:2503-2512.
10. deFilippi C.R., de Lemos J.A., Christenson R.H., et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010, 304:2494-2502.
11. Di Angelantonio E., Chowdhury R., Sarwar N., et al. B-type natriuretic peptides and cardiovascular risk: Systematic review and meta-analysis of 40 prospective studies. Circulation 2009, 120:2177-2187.
12. Drawz P.E., Sedor J.R. The genetics of common kidney disease: A pathway toward clinical relevance. Nat Rev Nephrol 2011, 7:458-468.
13. Elliott P., Chambers J.C., Zhang W., et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009, 302:37-48.
14. Erqou S., Kaptoge S., Perry P.L., et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302:412-423.
15. Esposito K., Pontillo A., Di Palo C., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: A randomized trial. JAMA 2003, 289:1799-1804.
16. Folsom A.R., Kronmal R.A., Detrano R.C., et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: The Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med 2008, 168:1333-1339.
17. Greenland P., Alpert J.S., Beller G.A., et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010, 122:e584-e636.
18. Harismendy O., Notani D., Song X., et al. 9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature 2011, 470:264-268.
19. Helgadottir A., Thorleifsson G., Manolescu A., et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007, 316:1491-1493.
20. Herder C., Karakas M., Koenig W. Biomarkers for the prediction of type 2 diabetes and cardiovascular disease. Clin Pharmacol Ther 2011, 90:52-66.
21. Ingelsson E., Schaefer E.J., Contois J.H., et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007, 298:776-785.
22. Kamstrup P.R., Tybjaerg-Hansen A., Steffensen R., et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009, 301:2331-2339.
23. Kathiresan S., Melander O., Anevski D., et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008, 358:1240-1249.
24. Khot U.N., Khot M.B., Bajzer C.T., et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003, 290:898-904.
25. Kim K.P., Einstein A.J., Berrington de González A. Coronary artery calcification screening: Estimated radiation dose and cancer risk. Arch Intern Med 2009, 169:1188-1194.
26. Kirschenlohr H.L., Griffin J.L., Clarke S.C., et al. Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat Med 2006, 12:705-710.
27. Lauer M.S. Screening asymptomatic subjects for subclinical atherosclerosis: Not so obvious. J Am Coll Cardiol 2010, 56:106-108.
28. Lee K.K., Cipriano L.E., Owens D.K., et al. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy. Circulation 2010, 122:1478-1487.
29. Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N Engl J Med 1998, 339:321-328.
30. Lewis G.D., Asnani A., Gerszten R.E. Application of metabolomics to cardiovascular biomarker and pathway discovery. J Am Coll Cardiol 2008, 52:117-123.
31. Lloyd-Jones D.M., Nam B.H., D'Agostino R.B., et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: A prospective study of parents and offspring. JAMA 2004, 291:2204-2211.
32. Lorenz M.W., Markus H.S., Bots M.L., et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-analysis. Circulation 2007, 115:459-467.
33. Manolio T. Novel risk markers and clinical practice. N Engl J Med 2003, 349:1587-1589.
34. Marenberg M.E., Risch N., Berkman L.F., et al. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994, 330:1041-1046.
35. Mayr M. Metabolomics: Ready for the prime time?. Circ Cardiovasc Genet 2008, 1:58-65.
36. McGill H.C., McMahan C.A. Determinants of atherosclerosis in the young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) research group. Am J Cardiol 1998, 82:30T-36T.
37. McPherson R., Pertsemlidis A., Kavaslar N., et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007, 316:1488-1491.
38. McQueen M.J., Hawken S., Wang X., et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): A case-control study. Lancet 2008, 372:224-233.
39. Melander O., Newton-Cheh C., Almgren P., et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009, 302:49-57.
40. Miller M., Zhan M., Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: The Third National Health and Nutrition Examination Survey. Arch Intern Med 2005, 165:2063-2068.
41. Morrow D.A., de Lemos J.A. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007, 115:949-952.
42. Musunuru K., Kathiresan S. Genetics of coronary artery disease. Annu Rev Genomics Hum Genet 2010, 11:91-108.
43. Nambi V., Chambless L., Folsom A.R., et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: The ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol 2010, 55:1600-1607.
44. O'Leary D.H., Polak J.F., Kronmal R.A., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999, 340:14-22.
45. Paynter N.P., Chasman D.I., Buring J.E., et al. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p213. Ann Intern Med 2009, 150:65-72.
46. Peden J., Hopewell J., Saleheen D., et al. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet 2011, 43:339-344.
47. Pencina M.J., D'Agostino R.B., D'Agostino R.B., et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172. Discussion: 207-112.
48. Pencina M.J., D'Agostino R.B., Demler O.V. Novel metrics for evaluating improvement in discrimination: Net reclassification and integrated discrimination improvement for normal variables and nested models. Stat Med 2012, 31:101-113.
49. Pignoli P., Tremoli E., Poli A., et al. Intimal plus medial thickness of the arterial wall: A direct measurement with ultrasound imaging. Circulation 1986, 74:1399-1406.
50. Pletcher M.J., Tice J.A., Pignone M., et al. Using the coronary artery calcium score to predict coronary heart disease events: A systematic review and meta-analysis. Arch Intern Med 2004, 164:1285-1292.
51. Polak J.F., Pencina M.J., Pencina K.M., et al. Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med 2011, 365:213-221.
52. Polonsky T.S., McClelland R.L., Jorgensen N.W., et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 2010, 303:1610-1616.
53. Rapsomaniki E., White I.R., Wood A.M., et al. A framework for quantifying net benefits of alternative prognostic models. Stat Med 2012, 31:114-130.
54. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
55. Ridker P.M., Paynter N.P., Rifai N., et al. C-reactive protein and parental history improve global cardiovascular risk prediction: The Reynolds risk score for men. Circulation 2008, 118:2243-2251.
56. Ridker P.M., Rifai N., Cook N.R., et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005, 294:326-333.
57. Ripatti S., Tikkanen E., Orho-Melander M., et al. A multilocus genetic risk score for coronary heart disease: Case-control and prospective cohort analyses. Lancet 2010, 376:1393-1400.
58. Rohatgi A., Patel P., Das S.R., et al. Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multi-ethnic population: Observations from the Dallas Heart Study. Clin Chem 2011, 58:172-182.
59. Rozanski A., Gransar H., Shaw L.J., et al. Impact of coronary artery calcium scanning on coronary risk factors and downstream testing the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial. J Am Coll Cardiol 2011, 57:1622-1632.
60. Rumberger J.A., Simons D.B., Fitzpatrick L.A., et al. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. Circulation 1995, 92:2157-2162.
61. Samani N.J., Erdmann J., Hall A.S., et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007, 357:443-453.
62. Saunders J.T., Nambi V., de Lemos J.A., et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation 2011, 123:1367-1376.
63. Schunkert H., König I.R., Kathiresan S., et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 2011, 43:333-338.
64. Shah S.H., Bain J.R., Muehlbauer M.J., et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet 2010, 3:207-214.
65. Smith G.D., Ebrahim S. Mendelian randomization: Prospects, potentials, and limitations. Int J Epidemiol 2004, 33:30-42.
66. Stein J.H., Korcarz C.E., Hurst R.T., et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: A consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008, 21:93-111.
67. Talmud P.J., Cooper J.A., Palmen J., et al. Chromosome 9p213 coronary heart disease locus genotype and prospective risk of CHD in healthy middle-aged men. Clin Chem 2008, 54:467-474.
68. van Kempen B.J., Spronk S., Koller M.T., et al. Comparative effectiveness and cost-effectiveness of computed tomography screening for coronary artery calcium in asymptomatic individuals. J Am Coll Cardiol 2011, 58:1690-1701.
69. Vasan R.S. Biomarkers of cardiovascular disease: Molecular basis and practical considerations. Circulation 2006, 113:2335-2362.
70. Walldius G., Jungner I., Holme I., et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet 2001, 358:2026-2033.
71. Wang T.J., Larson M.G., Levy D., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004, 350:655-663.
72. Wang T.J., Larson M.G., Vasan R.S., et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011, 17:448-453.
73. Wang Z., Klipfell E., Bennett B.J., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472:57-63.
74. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
75. Wilson P.W., Nam B.H., Pencina M., et al. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 2005, 165:2473-2478.
76. Wilson P.W., Pencina M., Jacques P., et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008, 1:92-97.
77. Wray N.R., Yang J., Goddard M.E., et al. The genetic interpretation of area under the ROC curve in genomic profiling. PLoS Genet 2010, 6:e1000864.
78. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004, 364:937-952.
79. Zethelius B., Berglund L., Sundström J., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008, 358:2107-2116.